Study of Ataluren (PTC124) in Hemophilia A and B

Phase 2

Terminated

Conditions: Hemophilia A
Hemophilia B

Interventions: Drug: Ataluren

Registration Number: NCT00947193

Lead Sponsor: PTC Therapeutics

Brief Summary: Hemophilia A (HA) and hemophilia B (HB) are inherited bleeding disorders caused by mutations in the gene for factor VIII (FVIII) and factor IX (FIX), respectively. These proteins are essential for blood clotting. The lack of FVIII/FIX can produce bleeding episodes that cause damage of the bone, muscles, joints, and tissues. A specific type of mutation, called a nonsense (premature stop codon) mutation, is the cause of the disease in approximately 10-30% of participants with hemophilia and results in severe manifestations. Ataluren (PTC124) is an orally delivered, investigational drug that acts to overcome the effects of the premature stop codon, potentially enabling the production of functional FVIII/FIX. This study is a Phase 2a trial evaluating the safety and efficacy of ataluren in participants with HA or HB due to a nonsense mutation. The main purpose of this study is to understand whether ataluren can safely increase FVIII/FIX activity levels.

Detailed Description: In this study, participants with hemophilia A or hemophilia B due to a nonsense mutation were treated with an investigational drug called ataluren (PTC124). Evaluation procedures to determine if a participant qualifies for the study was performed within 14 days prior to the start of treatment. Eligible participants who elected to enroll in the study then participated in a 28-day treatment period. Within the 28-day period, ataluren (PTC124) treatment was to be taken for 2 cycles of 14 days each 3 times per day with meals at a dose level of 5, 5, 10 milligrams/kilograms (mg/kg) in the first cycle and a dose level of 20, 20, 40 mg/kg in the second cycle. After the first 14-day cycle, study doses were changed to 10 mg/kg (morning), 10 mg/kg (midday), and 20 mg/kg (evening) and the doses were administered for 1 cycle only. Then, there was an interval of approximately 14 days without treatment. During the study, ataluren (PTC124) efficacy, safety, and pharmacokinetics were evaluated periodically with measurement of FVIII/FIX activity and inhibitor levels, other blood tests, and urinalysis.

Recruitment & Eligibility

Status: TERMINATED

Sex: Male

Target Recruitment: 13

Inclusion Criteria

Ability to provide written informed consent
Age ≥18 years
Presence of a nonsense mutation as the sole disease-causing mutation in the FVIII or FIX gene
At least 20 prior treatments with FVIII or FIX concentrates
Willingness and ability to comply with scheduled visits, drug administration plan, study restrictions, and study procedures

Exclusion Criteria

Known hypersensitivity to any of the ingredients or excipients of the study drug
Any history of prior anti-FVIII/FIX inhibitors
Unable or unwilling to forego prophylactic FVIII/FIX concentrate use during the screening and on-study periods (Note: Participants were allowed use of FVIII/FIX concentrates for treatment of bleeding episodes while on study)

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ataluren Overall Study	Ataluren	Ataluren was provided as a vanilla-flavored powder to be mixed with water or milk. Ataluren was taken 3 times per day, with dosing based on the participant's body weight. The dose level for ataluren was 5 mg/kg in the morning, 5 mg/kg at midday, and 10 mg/kg in the evening or 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by an interval of 14 days without treatment.

Primary Outcome Measures

Name	Time	Method
Number of Participants With a Plasma FVIII/FIX Activity Response at Day 14	Baseline up to Day 14	A plasma FVIII/FIX activity response was defined as an end-of-treatment (Day 14) activity of ≥1%.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With a Change From Baseline in Plasma Anti-FVIII/FIX Inhibitor Titers at Day 14	Baseline and Day 14	To assess the change from Baseline in plasma anti-FVIII/FIX inhibitor titers, it was determined if any potential antibodies were neutralizing using the Bethesda assay. The Bethesda assay demonstrates antibodies that are neutralizing by quantifying residual FVIII/FIX activity in normal plasma after serial dilutions with participant plasma. For this assay, the neutralizing antibody threshold value was 0.6 Bethesda units (BU).
Ataluren Plasma Exposure	Day 10 (pre-dose) and Day 14 (post-dose)	The ataluren plasma concentrations before and 2 hours after the first morning dose at end of treatment was measured.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) by Severity and Relationship to Study Drug	Baseline up to Day 28	The relationship of TEAEs and SAEs to the study drugs was assessed as: probable related, possible related, unlikely related, and unrelated. The severity of TEAEs were graded using the Common Terminology Criteria for Adverse Events, Version 3.0, as: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), or Grade 5 (fatal). A summary of other non-serious adverse events (AEs) and all serious AEs, regardless of causality is located in Reported AE section.
Number of Participants With a Clinically Meaningful Abnormal Clinical Laboratory (Hematology, Adrenal Assays, Biochemistry, and Urinalysis) Parameters	Baseline up to Day 28	The Investigator used his/her judgment in determining whether an abnormality was clinically significant, diagnostic evaluation was warranted, and potential interruption of ataluren was appropriate. Life-threatening (Grade 4) or severe (Grade 3) laboratory abnormalities were considered dose-limiting, although recurrent or persistent moderate (Grade 2) events were also considered dose-limiting in certain circumstances. Values considered abnormal included -Hematology: Serum total bilirubin Grade 2 (\>1.5-3.0\upper limit of normal \[ULN\]) and Serum alanine aminotransferase, Serum aspartate aminotransferase, and Serum gamma glutamyl transferase Grade 2 (\>2.5-3.0\ULN); -Adrenal: Plasma adrenocorticotropic hormone \>ULN (and cortisol within normal limits); and -Renal: serum creatinine Grade 1 (\>ULN-1.5\ULN) and Serum blood urea nitrogen ≥1.5-3.0\ULN. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Occurrence of Bleeding Episodes	Baseline up to Day 28	Frequency, timing, anatomic location, and severity of any bleeding episodes were recorded. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Compliance With Ataluren Administration	Baseline up to Day 28	Ataluren compliance as assessed by quantification of used and unused drug. Data were not collected or analyzed for this measure because participants were terminated early from the study.

Trial Locations

Locations (13): Children's Hospital of Philadelphia
🇺🇸
Philadelphia, Pennsylvania, United States
The Bleeding and Clotting Disorders Institute
🇺🇸
Peoria, Illinois, United States
Azienda Ospedaliero-Universitaria Careggi Viale G.B. Morgagni
🇮🇹
Firenze, Italy
Hôpital Cardiologique
🇫🇷
Lille Cedex, France
New England Hemophilia Center
🇺🇸
Worcester, Massachusetts, United States
Cincinnati Children's Hospital Medical Center
🇺🇸
Cincinnati, Ohio, United States
St. Vincent Indianapolis Hospital
🇺🇸
Indianapolis, Indiana, United States
Puget Sound Blood Center
🇺🇸
Seattle, Washington, United States
A.Bianchi Bonomi Hemophilia and Thrombosis Center
🇮🇹
Milano, Italy
Vanderbilt Hemostatis and Thrombosis Clinic
🇺🇸
Nashville, Tennessee, United States
St. Paul's Hospital
🇨🇦
Vancouver, British Columbia, Canada
Hôpital Necker Enfants Malades
🇫🇷
Paris, France
Hôpital Edouard Herriot
🇫🇷
Lyon Cedex, France